

## Tefin Suppositories Ibuprofen

**Dosing Table for Tefin 75mg Suppositories Ibuprofen.**

Age	Body weight	Single dose	Maximum daily dose Number of suppositories (corresponding amount of ibuprofen)
8 to 12 months	7.5 to 10 kilograms	1 suppository (75 milligram)	3 suppositories (225 milligram daily)
12 months to 3 years	10 to 15 kilograms	1 suppository (75 milligram)	4 suppositories (300 milligram daily)



GMS Code: 61734 **P**

**Dosing Table for Tefin 150mg Suppositories Ibuprofen.**

Age	Body weight	Single dose	Maximum daily dose Number of suppositories (corresponding amount of ibuprofen)
3 to 6 years	15 to 20 kilograms	1 suppository (150 milligram)	3 suppositories (450 milligram daily)
6 to 9 years	20 to 29 kilograms	1 suppository (150 milligram)	4 suppositories (600 milligram daily)



GMS Code: 62983 **P**

**Tefin are the only Ibuprofen Suppositories on the GMS and Community Drug Schemes.**



**Abbreviated Prescribing Information (see SPC for full details)**

**Name of the Medicinal Products:** Tefin 75 mg Suppositories and Tefin 150mg Suppositories. Tefin Suppositories contain ibuprofen. **Therapeutic Indications:** For the symptomatic treatment of mild to moderate pain and fever. **Posology and method of administration:** See dosing tables. Tefin suppositories should be put deep into the rectum after a bowel movement. They may be warmed up in the hands or dipped for a short time into warm water to improve their sliding properties. **Contraindications** Hypersensitivity to ibuprofen, aspirin or other NSAIDs or to any of the excipients, disorders of blood count, active gastric or duodenal ulcer or haemorrhage, cerebrovascular or other active bleeding, severe impairment of liver or kidney function, severe cardiac failure, patients in the last three months of pregnancy. **Special warnings and precautions for use:** Caution in the following groups: patients with gastrointestinal conditions, elderly, patients with cardiovascular disease, hypertension, heart failure, porphyria, impaired renal function, hepatic dysfunction, hay fever, asthma or allergies, patients at risk for thrombotic events and patients with blood disorders. Particular caution with long-term treatment or higher doses in patients with risk factors for cardiovascular disease or thrombotic events. **Pregnancy and breastfeeding:** Caution in pregnancy and in breastfeeding. **Interaction with other medicinal products and other forms of interaction:** Caution in combination with the following active substances: Other NSAIDs including salicylate, digoxin, phenytoin, lithium, diuretics, ACE inhibitors, adrenergic beta-antagonists and angiotensin-II inhibitors, glucocorticoids, platelet aggregation inhibitors like acetylsalicylic acid and selective serotonin uptake inhibitors, methotrexate, ciclosporin, anticoagulant agents, sulphonylureas, tacrolimus, zidovudine, probenecid and sulphapyrazone. Ibuprofen may negate the cardioprotective effect of acetylsalicylic acid. **Undesirable effects:** Cardiac disorders, blood and lymphatic system disorders, nervous system disorders, eye disorders, ear and labyrinth disorders, gastrointestinal disorders, local irritation and bleeding, renal and urinary disorders, skin and subcutaneous tissue disorders, aggravation of infections and infestations, vascular disorders, hypersensitivity reactions, hepatobiliary disorders and psychiatric disorders. **Overdose:** Overdosing may lead to CNS-related disorders, gastrointestinal bleeding and dysfunction of liver and kidney. There is no specific antidote.

**Shelf life:** 5 years. **Special precautions for storage:** Do not store above 25°C.

**Marketing authorisation holder:** Carysfort Healthcare Limited, 93 Carysfort Park, Blackrock Co. Dublin, Ireland

**Marketing authorisation number:** PA 1684/1/1-2

**Date of preparation:** April 2016